• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

Validation Data Gallery

Filter:
  • Western Blot (WB) analysis of various lysates using SUMF2 Polyclonal antibody (11210-1-AP)

    WB analysis using 11210-1-AP

    A431 cell lysates were subjected to SDS PAGE followed by western blot with 11210-1-AP (SUMF2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours.

  • Western Blot (WB) analysis of human spleen tissue using SUMF2 Polyclonal antibody (11210-1-AP)

    WB analysis of human spleen using 11210-1-AP

    human spleen tissue were subjected to SDS PAGE followed by western blot with 11210-1-AP (SUMF2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours.

  • Western Blot (WB) analysis of human skin tissue using SUMF2 Polyclonal antibody (11210-1-AP)

    WB analysis of human skin using 11210-1-AP

    human skin tissue were subjected to SDS PAGE followed by western blot with 11210-1-AP (SUMF2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours.

  • Immunoprecipitation (IP) experiment of A431 cells using SUMF2 Polyclonal antibody (11210-1-AP)

    IP experiment of A431 using 11210-1-AP

    IP result of anti-SUMF2 (IP:11210-1-AP, 4ug; Detection:11210-1-AP 1:2000) with A431 cells lysate 2640 ug.

  • Immunoprecipitation (IP) experiment of HeLa cells using SUMF2 Polyclonal antibody (11210-1-AP)

    IP experiment of HeLa using 11210-1-AP

    IP result of anti-SUMF2 (IP:11210-1-AP, 4ug; Detection:11210-1-AP 1:2000) with HeLa cells lysate 1560 ug.

  • Immunohistochemistry (IHC) staining of human breast cancer tissue using SUMF2 Polyclonal antibody (11210-1-AP)

    IHC staining of human breast cancer using 11210-1-AP

    Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 11210-1-AP (SUMF2 antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • Immunohistochemistry (IHC) staining of human breast cancer tissue using SUMF2 Polyclonal antibody (11210-1-AP)

    IHC staining of human breast cancer using 11210-1-AP

    Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 11210-1-AP (SUMF2 antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • Immunofluorescence (IF) / fluorescent staining of A431 cells using SUMF2 Polyclonal antibody (11210-1-AP)

    IF Staining of A431 using 11210-1-AP

    Immunofluorescent analysis of (-20°C Methanol) fixed A431 cells using SUMF2 antibody (11210-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

［PR］まずは試したいあなたに。トライアルサイズも特別価格 >>『PRIME BUY抗体特割キャンペーン（4/21～）』

SUMF2 Polyclonal antibody

SUMF2 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Cat No. 11210-1-AP
Publications(2)

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, IF/ICC, IP, ELISA

Synonyms

Sulfatase-modifying factor 2, sulfatase modifying factor 2, PSEC0171, pFGE, Paralog of formylglycine-generating enzyme

Formulation:  PBS and Azide
PBS and Azide
Conjugate:  Unconjugated
Unconjugated
CoraLite® Plus 488
Size/Concentration: 

-/ -

ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。

国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター（国内）に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。

保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換／補填対応を承ります。詳細はこちらをご覧ください。

Tested Applications

Positive WB detected inA431 cells, human skin tissue, human spleen tissue
Positive IP detected inA431 cells, HeLa cells
Positive IHC detected inhuman breast cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF/ICC detected inA431 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:5000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

11210-1-AP targets SUMF2 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen SUMF2 fusion protein Ag1711 相同性解析による交差性が予測される生物種
Full Name sulfatase modifying factor 2
Calculated molecular weight 34 kDa
Observed molecular weight 34 kDa
GenBank accession numberBC015600
Gene Symbol SUMF2
Gene ID (NCBI) 25870
RRIDAB_2255511
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
UNIPROT IDQ8NBJ7
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Protocols

Product Specific Protocols
WB protocol for SUMF2 antibody 11210-1-APDownload protocol
IHC protocol for SUMF2 antibody 11210-1-APDownload protocol
IF protocol for SUMF2 antibody 11210-1-APDownload protocol
IP protocol for SUMF2 antibody 11210-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
ratWB,IHC

Int J Clin Exp Pathol

Downregulation of SUMF2 gene in ovalbumin-induced rat model of allergic inflammation.

Authors - Chuanfeng Fang
View Article
humanWB,IHC

Front Immunol

Advancing bladder cancer management: development of a prognostic model and personalized therapy

Authors - Xiang Huang
View Article